Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leflunomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH known ✓ | Q02127 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | CCKBR | P32239 | 1/20 | 1.00 |
| ▸ | MC4R | P32245 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leflunomide SCHEMBL5057 | 1.00 | RAB9A (1.00) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| Leflunomide SCHEMBL29271960 | 0.96 | RAB9A (0.92) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| SCHEMBL11428900 | 0.94 | RAB9A (0.88) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| SCHEMBL8812525 | 0.93 | RAB9A (0.86) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| Leflunomide SCHEMBL18584841 | 0.92 | RAB9A (0.84) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| SCHEMBL12356679 | 0.90 | DHODH (0.82) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| SCHEMBL26075462 | 0.89 | DHODH (0.81) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| SCHEMBL9812368 | 0.87 | RAB9A (0.78) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| SCHEMBL7459817 | 0.86 | DHODH (0.76) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| SCHEMBL1826746 | 0.85 | RAB9A (0.73) | RAB9ADHODHNPC1SMN1; SMN2GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 565 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080206237-A1 | Synergistic Combination Of Xolair/Omalizumab/E25 With Immunosuppressive Agent | OWEN CHARLES EDWARD | 2008-08-28 | — | — | US | claimed |
| EP-1846031-A1 | SYNERGISTIC COMBINATION OF XOLAIR/OMALIZUMAB/E25 WITH IMMUNOSUPPRESSIVE AGENT | Novartis AG (CH) | 2007-10-24 | — | — | EP | claimed |
| WO-2006082052-A1 | SYNERGISTIC COMBINATION OF XOLAIR/OMALIZUMAB/E25 WITH IMMUNOSUPPRESSIVE AGENT | NOVARTIS AG (CH) | 2006-08-10 | — | — | WO | claimed |
| WO-2005079419-A2 | METHODS OF TREATING IMMUNOPATHOLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-01 | — | — | WO | claimed |
| EP-4398904-A1 | SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3645001-B1 | MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF | G1 THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240199583-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2024-06-20 | — | — | US | disclosed |
| US-12006307-B2 | Pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20240158418-A1 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | C4 THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2024097980-A1 | RET-LDD PROTEIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097989-A1 | RET-LDD PROTEIN DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH | 2003-07-31 | — | — | US | disclosed |
| US-20030114444-A1 | [[2-(Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain | WYETH | 2003-06-19 | — | — | US | disclosed |
| WO-2003048122-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003031416-A2 | [[2-(AMINO-3,4-DIOXO-1CYCLOBUTEN-1-YL)AMINO]ALKYL]-ACID DERIVATIVES FOR THE TREATMENT OF PAIN | WYETH (US) | 2003-04-17 | — | — | WO | disclosed |
| US-20020107284-A1 | Inhibitors of the EGF-receptor tyrosine kinase and methods for their use | PARKER HUGHES INSTITUTE (US) | 2002-08-08 | — | — | US | disclosed |
| US-6355678-B1 | ANTICANCER AGENTS; ENZYME INHIBITOR | PARKER HUGHES INSTITUTE | 2002-03-12 | — | — | US | disclosed |
| EP-1124795-A1 | INHIBITORS OF THE EGF-RECEPTOR TYROSINE KINASE AND THEIR USE | Parker Hughes Institute (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000056703-A1 | INHIBITORS OF THE EGF-RECEPTOR TYROSINE KINASE AND THEIR USE | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158418-A1 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | EGFR, ERBB2, ERBB3 | DHODH 3054/4885RAB9A 1782/4885NPC1 2686/4885 |
| US-20020107284-A1 | Inhibitors of the EGF-receptor tyrosine kinase and methods for their use | EGFR, ERBB2, ERBB3 | DHODH 2455/4885RAB9A 3079/4885NPC1 4248/4885 |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | DHODH 1506/4885RAB9A 3792/4885NPC1 3838/4885 |
| US-20030114444-A1 | [[2-(Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain | OPRD1, OPRL1, OPRK1 | DHODH 1780/4885RAB9A 2933/4885NPC1 2877/4885 |
| US-12006307-B2 | Pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | DHODH 315/4885RAB9A 1851/4885NPC1 308/4885 |
| US-20240199583-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | DHODH 524/4885RAB9A 2300/4885NPC1 1197/4885 |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | PLA2G4A, PLA2G4B, PLA2G4C | DHODH 2134/4885RAB9A 1772/4885NPC1 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.